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ABSTRACT 
Background: This study aimed to evaluate the non-inferiority and safety of a newly developed preservative-free (PF) multi-dose 
latanoprost/timolol ophthalmic solution, compared with the benzalkonium chloride (BAK)-preserved fixed combination, in patients with open-
angle glaucoma and ocular hypertension. 
Methods: A Phase III randomized multi-center observer-blind parallel-group clinical trial was conducted. A total of 210 adult patients (aged 
over 18 years) were randomly treated with the PF- or the BAK-preserved latanoprost/timolol solution once daily in the affected eye(s) for 12 
weeks. Follow-up visits were scheduled at weeks 2, 6, and 12; intraocular pressure (IOP) was recorded at 8:00 AM, 12:00 PM, and 4:00 PM. 
The primary efficacy endpoint to prove non-inferiority was the IOP change at 8:00 AM (± 1 hour) from the baseline to the end of treatment 
(week 12) in the studied eye. Safety parameters were also assessed. 
Results: In total, 196 patients completed the study. The pressure-lowering effect of the PF eye drops was comparable to that of the preserved 
formulation at all-time points. Latanoprost/timolol PF formulation was non-inferior to the BAK-preserved solution as shown by the change in 
IOP from day 0 to week 12. The point estimate of the inter-treatment difference was 0.624 mmHg (95% CI: -0.094, 1.341). Both treatments 
were well-tolerated during the study, and they had similar adverse event profiles. 
Conclusions: PF-latanoprost/timolol combination was found to be non-inferior to the BAK-preserved formulation based on the efficacy at all 
times, with similar local tolerance. 
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INTRODUCTION 
Open-angle glaucoma is a progressive optic disc neuropathy 
that has become one of the most prominent causes of 
irreversible vision loss globally [1]. Glaucoma affects more 
than 70 million people globally, with a prevalence of 3.5% in 
patients aged 40-80 years [2, 3]. Clinical studies have 
confirmed the significance of high intraocular pressure (IOP) 
in the development and progression of this disease [4]. The 
decrease in this modifiable ocular parameter continues to be 
the cornerstone of glaucoma treatment, with topical 
medications still being the first-line option for the disease [1, 
5]. 
Prostaglandin analogs and β-adrenergic receptor blocking 
agents have become the mainstay of glaucoma treatment 
due to their increased potency and safety [6]. In this respect, 
the fixed combination of latanoprost, the prostaglandin 
analog, and timolol, a β-adrenergic blocker, is approved for 
the treatment of open-angle glaucoma and ocular 
hypertension in patients with glaucoma that is not 
sufficiently controlled with monotherapy [7]. 
Latanoprost, an IOP-lowering medication, is a widely used 
prostaglandin analog that acts primarily by increasing the 
outflow of aqueous humor, whereas timolol decreases 
aqueous humor formation in the ciliary epithelium [7]. The 
two drugs have shown additive IOP-lowering effects when 
administered together, with several short- and long-term 
clinical trials validating the favorable efficacy and safety 
profile of their topical combination [8, 9]. 
Xalacom™ (Pfizer, Kent, UK), a fixed latanoprost/timolol 
combination, was first approved in the EU in 2000 and is now 
available in several countries [1]. The marketed multi-dose 
formulation contains benzalkonium chloride (BAK), a 
commonly used and highly effective antimicrobial agent with 
a broad range of activities, as a preservative [5, 6]. Studies 
have shown that the non-specificity of the antimicrobial 
activity of BAK may result in tolerability issues in some cases 
[6]. BAK, a quaternary ammonium, may be responsible for 
cases of corneal epithelial cellular dysfunction, conjunctival 
inflammation and fibrosis, and disorders of deeper ocular 
tissues associated with long-term treatment [4, 10]. Results 
from clinical studies have demonstrated a higher incidence of 
such effects in the presence of BAK, with remission of 
symptoms following the withdrawal of the preservative [11, 
12].  
In light of these effects, several topical antiglaucoma 
medications have been developed as preservative-free 
formulations over the last few years. Different beta-blockers, 
prostaglandin analogs, and fixed combination products have 
been commercialized as preservative-free formulations and 
marketed mainly as single-dose units [13]. A preservative-
free formulation of a fixed latanoprost/timolol combination 
has also been marketed recently and is available in sterile 
unit-dose vials [14]. However, the relatively higher cost and 
the increased potential of mishandling these formulations, 
leading to an increased risk of contamination, have been 
reported [13]. 
In this respect, novel multi-dose preservative-free 
formulations of high quality that are easy to use have been 
developed [15]. One such product is the newly developed 
preservative-free latanoprost 50 μg/mL + timolol 5 mg/mL 
eye drop solution (Pharmathen S.A., Athens, Greece), which 
is packaged in a multi-dosage container with the Aero Pump 
3K technology to provide adequate contamination 
protection over repeated use through its specialized filtration 
and valve systems. To compare the efficacy and safety 
profiles of this novel preservative-free latanoprost/timolol 
fixed-combination and the BAK-preserved formulation 
(Xalacom™), a non-inferiority phase III study involving 
patients with open-angle glaucoma and ocular hypertension 
was conducted. 
METHODS 
Study design and participants 
This was a national multicenter randomized reference-
controlled observer-blind non-inferiority parallel-group 
phase III clinical trial comparing the preservative-free 
ophthalmic product of latanoprost 50 μg/mL + timolol 5 
mg/mL eye drops solution (Pharmathen S.A., Athens, Greece) 
with the marketed BAK-preserved Xalacom™ (Latanoprost 
50μg/ml + timolol 5 mg/mL, Pfizer, Kent, UK) eye drop 
solution in patients with open-angle glaucoma and ocular 
hypertension over 3 months. The study was conducted at 
eight clinical sites in Greece (Ophthalmiatreio Athens, 
General Hospital of Larissa, General University Hospital of 
Athens Attikon, General University Hospital of Thessaloniki 
AHEPA, IASO Thessalias, General University Hospital of Patra, 
General Hospital of Thessaloniki Ippokrateio, and NIMITS 
417) between June 2018 and December 2018. The study 
protocol was prospectively approved by the National 
(Hellenic) Ethics Committee (NEC) (October 31, 2018) and the 
National (Hellenic) Organization of Medicines (EOF) (October 
31, 2018) and performed in accordance with the Declaration 
of Helsinki (2004) and Good Clinical Practice (GCP) guidelines. 
Before the initiation of the study, written informed consent 
was obtained from all participants. The study was registered 
in the EU Clinical Trials Register database with trial 
identification number 2017-004524-29.  
Male or female patients aged ≥18 years who (a) were 
diagnosed with unilateral or bilateral open-angle glaucoma 
or ocular hypertension, (b) had non-efficiently controlled IOP, 
and (c) had not used anti-glaucoma treatment for at least 4 
weeks before the study initiation were included based on 
eligibility criteria per trial. IOP had to be between 22 and 35 
mmHg when measured at 8:00 AM, 12:00 PM, and 4:00 PM 
before the treatment in at least one eye at day 0, and the 
best-corrected visual acuity had to be ≥20 of 100 (Snellen), 
which is equal to the logarithm of the minimum angle of 
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resolution (LogMAR) value of 0.7. The main exclusion criteria 
were as follows: history of chronic or recurrent inflammatory 
eye disease, ocular trauma, or infections; history of anterior 
chamber lens, torn posterior lens capsule, aphakia, or any 
known risk factor for cystoid macular edema, narrow-angle 
glaucoma and angle-closure glaucoma, compromised cornea 
or corneal abnormalities, retinal disease with clinical 
significance or progressive entity, intraocular surgery within 
the past 3 months or ocular laser surgery within the past 1 
month; cup/disk ratio of >0.8; current use of topical, ocular, 
nonsteroidal anti-inflammatory drugs; history of airway or 
cardiovascular disease and pregnancy, breast-feeding, or 
childbearing potential.   
The sample size of the current study was calculated to obtain 
the required power for the demonstration of non-inferiority 
of the IOP change from the baseline of the test compared to 
that of the control formulation. For this sample size 
calculation, the one-sided significance level was set at 2.5%, 
and the power was 80%. A non-inferiority margin of 1.5 
mmHg, used as the tolerance criterion, has been 
conventionally used and accepted in non-inferiority 
glaucoma studies [16, 17], based on the assumption of a 
value of 2.8 for the common standard deviation (SD) of the 
inter-group difference and a value of 0.3 for the true mean 
difference between the treatment groups. Considering these 
assumptions, a total sample size of 174 was used for this 
study, and the enrolled patients were equally and randomly 
allocated to the treatment groups. In addition, as the primary 
analysis was based on the per-protocol (PP) population, a 
dropout rate of approximately 20% was further assumed, 
resulting in a total sample size of 210 as a prerequisite for an 
adequately powered study (i.e., 105 patients per treatment 
group). 
During the baseline visit (day 0), eligible patients were 
randomly assigned to receive the preservative-free multi-
dose latanoprost 50 μg/mL + timolol 5 mg/mL fixed 
combination product (Pharmathen S.A.; test product group) 
or the BAK-preserved control formulation (Xalacom™, Pfizer; 
control product group) for 12 weeks. Because of the 
differences between the packaging of both drugs, this trial 
was conducted as observer-blind. Hence, the treatment 
allocation was conducted by personnel other than the 
investigator to guarantee investigator masking.  
The patients were instructed to instill one drop in the 
affected eye(s) once daily in the evening (at approximately 
8:00 PM) and scheduled for follow-up visits at weeks 2 and 6 
( ±2 days) and 12 ( ±4 days). Since the treatments were 
administered by the patients at home, compliance control 
was also performed at each visit and at the end of the 
treatment by visual inspection of the amount of solution in 
the bottle. In this respect, the patients were asked to return 
full and empty bottles of eye drops at the end of the clinical 
trial. Compliance was documented in the patient’s diary. The 
information recorded included the date and time of each 
instillation, and the patient was obliged to bring the diary 
during every scheduled visit (weeks 2, 6, and 12).  
Using a calibrated Goldmann applanation tonometer at each 
study visit, the IOP levels were measured and recorded by 
blinded evaluators twice for each eye at four-hour intervals: 
8:00 AM, 12:00 PM, and 4:00 PM (±1 h). If the two 
measurements of the same eye differed by more than 4 
mmHg, a third measurement was performed, and the 
average value was used in the analysis. In patients with 
bilateral disease, if only one eye met the eligibility criteria 
(clinical trial eye), the contralateral eye was treated if it did 
not meet the exclusion criteria. If both eyes were eligible, the 
eye with a higher IOP was included. If both eyes had the same 
IOP, the investigator decided on the study eye. 
Patient Involvement  
Patients were not directly involved in the design of this study 
or the writing or editing of this document. 
Efficacy Assessments 
The primary efficacy endpoint for confirming non-inferiority 
was the change in IOP from day 0 to the end of week 12 (± 4 
days) in the study eye. The mean IOP (average of two or three 
consecutive IOP measurements) was measured at the same 
time (8:00 AM ± 1 h) for each visit. 
The secondary efficacy variables included (i) the change in 
IOP at 12:00 PM and 4:00 PM in the study eye from day 0 to 
week 12 (± 4 days), (ii) the change in IOP at 8:00 AM, 12:00 
PM, and 4:00 PM from day 0 to week 2 (± 2 days), and (iii) the 
change in IOP at 8:00 AM, 12:00 PM, and 4:00 PM in the study 
eye from day 0 to week 6.  
In addition, the investigator re-evaluated the following 
parameters on weeks 2, 6, and 12: blood pressure, heart rate, 
changes in concomitant medication, visual acuity, 
ophthalmoscopy, intraocular pressure, ocular discomfort, 
adverse events, and evaluation of treatment compliance 
(collection of used and unused clinical trial drugs). 
Safety Assessments 
The evaluation of the safety parameters was based on the 
recordings of the ocular and systemic adverse events (AEs) 
along with their severity (mild, moderate, or severe) and their 
potential relationship with the study treatment, any clinically 
significant safety findings during the ocular examination, and 
any decrease in visual acuity from the baseline (day 0). The 
safety population (SP) comprised all patients who had 
received at least one eye drop of the preservative-free or 
BAK-preserved preparation. 
Statistical Analyses 
The principal statistical hypothesis of the study was that the 
new preservative-free formulation of latanoprost 50 μg/mL + 
timolol 5 mg/mL eye drops solution is non-inferior, in terms 
of efficacy, to Xalacom™ (Latanoprost 50μg/ml + timolol 5 
mg/mL). In this respect, an analysis of covariance (ANCOVA) 
model was used to analyze the IOP change, with the 
 
Med Hypothesis Discov Innov Ophthalmol. 2020; 9(4)  
258 NON-INFERIORITY EVALUATION OF PF XALACOM VERSUS XALACOM IN PATIENTS WITH HIGH IOP 
treatment and baseline IOP as the main effect and covariate, 
respectively. The treatment difference and two-sided 95% 
confidence intervals (CIs) for the difference were calculated. 
The preservative-free latanoprost/timolol solution was 
considered to be non-inferior to the marketed BAK-
preserved Xalacom™, if the upper limit for the 95% CI of the 
difference was < 1.5 mmHg [16, 17]. 
Continuous secondary efficacy variables, to be used as 
additional supportive evidence, were also analyzed using the 
ANCOVA model with the respective baseline IOP as the 
covariate and treatment as a factor. The treatment 
difference and two-sided 95% CI for the difference were also 
obtained for the secondary endpoints. 
The demographic and baseline characteristics for the 
treatment groups were compared using the parametric 
independent t-test or the non-parametric Mann-Whitney U-
test for continuous variables and the chi-squared test or 
Fisher’s exact test for categorical variables. The safety data 
were compared, when appropriate, using the chi-squared 
test or Fisher’s exact test, depending on the nature of the 
data. Statistical significance was set at P < 0.05. IBM SPSS 
Statistics for Windows, version 24 (IBM Corp., Armonk, NY, 
USA), was used to conduct all analyses.  
The subjects were categorized into two groups. The intent-
to-treat (ITT) population included all randomized patients 
with one post-baseline IOP measurement, whereas the per-
protocol (PP) population included all subjects of the ITT 
population with no substantial protocol violations who 
completed all IOP measurements, completed at least 12 
weeks of treatment, and did not take prohibited concurrent 
medications. Statistical analysis of the primary efficacy 
variable was performed for the PP population.  
RESULTS 
Patient baseline characteristics and disposition  
A total of 210 patients were randomized into two groups and 
administered treatment; 106 patients received the test 
formulation, and 104 patients received the control 
formulation. Fourteen (14) patients were excluded from the 
PP population (test, n = 10; control, n = 4) due to consent 
withdrawal, adverse events, or protocol violations. Thus, 196 
patients (test, n = 96; control, n = 100) were included in the 
PP population (Figure 1). The ITT population included 209 
randomized patients, as one patient had no post-dose IOP 
measurements. The safety population (SP) included all 
randomized patients who were instilled with one dose of the 
study medication (n = 210).  
Table 1 shows the patient characteristics at baseline. 
The demographic and clinical characteristics were 
similar in the two treatment groups at baseline (P > 
0.05). All the recruited subjects had well-controlled IOP 
before inclusion in the study. The difference between 
the IOPs of the test and control groups during all three 
baseline measurements at 8:00 AM, 12:00 PM, and 4:00 
PM was not significant (P > 0.05 for all measurements). 
Treatment compliance was fairly good, as the patients 
missed less than 20% of the planned administered 




Table 1. Patient characteristics and baseline data for the preservative-free (PF) test formulation (Latanoprost 50 μg/ml + Timolol 5mg/ml eye drops 
solution) and the BAK-preserved formulation (Xalacom™), which was the control formulation for the PP population.  
 Preservative-free  
test product 
(N = 96) 
BAK-preserved  
control product 
(N = 100) 
P-value 
Age, years Mean (SD) 69.48 (11.73) 70.92 (10.97) 0.378 
Sex, Females, n(%) 52 (54.2) 49 (49.0) 0.469 
Caucasians, n(%)  96 (100.0) 100 (100.0) 0.999 
Open-angle glaucoma, n(%) 66 (68.8) 71 (71.0) 0.731 
Bilateral disease, n(%) 77 (80.2) 82 (82.0) 0.749 
Comorbidities, n(%) 77 (80.2) 78 (78.0) 0.704 
History of allergies, n(%) 3 (3.1) 3 (3.0) 0.959 
Concomitant medications, n(%) 76 (79.2) 75 (75.0) 0.488 
History of ocular surgery, n(%) 41 (42.7) 43 (43.0) 0.967 
History of ocular laser surgery, n(%) 8 (8.3) 4 (4.0) 0.206 
IOP mmHg at 8:00 AM [mean (SD)] 24.60 (2.07) 25.03 (2.39) 0.184 
IOP mmHg at 12:00 PM [mean (SD)] 24.36 (1.71) 24.79 (2.19) 0.133 
IOP mmHg at 4:00 PM [mean (SD)] 24.37 (1.85) 24.44 (2.00) 0.813 
Abbreviations: BAK, Benzalkonium chloride; IOP, intraocular pressure; n, number; %, percentage; SD, Standard deviation; PP population, per-protocol 
population; AM, means before midday; PM, means after midday. 
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Figure 1. Disposition of patients treated with the preservative-free latanoprost/timolol formulation (Pharmathen S.A.) and the BAK-preserved control 
formulation Xalacom™ (Latanoprost 50μg/ml + timolol 5 mg/mL, Pfizer) . Abbreviations: BAK, benzalkonium chloride; PF, preservative-free; ITT, Intent To 
Treat population; N, number; SP, Safety Population. 
Efficacy  
The non-inferiority of the test was based on the per-
protocol dataset. In the PP population, the primary 
efficacy endpoint, which is the mean IOP change at 8:00 
AM from the baseline (day 0) to the end of treatment 
(week 12), demonstrated that the preservative-free 
formulation was non-inferior to the existing BAK-
preserved product. In particular, the mean ± SD of the 
IOP decreased from 24.60 ± 2.07 mmHg at day 0 to 
16.72 ± 2.89 mmHg at week 12 (final visit) in the 
preservative-free group and from 25.03 ± 2.39 mmHg 
to 16.37 ± 2.90 mmHg at the same time points for the 
BAK-preserved product (Table 2). The point estimate of 
the difference between the test and control products 
was 0.624 mmHg (95% CI: -0.094, 1.341) after adjusting 
for the respective baseline IOP measurements. Non-
inferiority was demonstrated at week 12, as the upper 
limit of the 95% CI for the difference between the two 
treatments was below 1.5 mmHg. The statistically non-
significant differences between the changes in IOP in 
the two treatment groups from baseline at all the time 
points for each visit were further obtained during the 
evaluation of the secondary efficacy variables 
supporting the primary efficacy analysis (Table 2). 
Figure 2 shows the change in mean IOP for the test (PF) 
and control (BAK) treatment groups, as measured at 
8:00 AM during the four study visits (day 0-baseline and 
weeks 2, 6, 12). These results were further confirmed 
by the evaluations of the ITT population. For the 
primary endpoint, the point estimate of the difference 
between the IOP changes caused by the test and 
control formulations at 8:00 AM in week 12 was T-C = 
0.442 and the corresponding 95% CI was (-0.271, 
1.156), after adjusting for the respective baseline IOP 
measurements. The difference was not statistically 
significant (P = 0.223). Thus, the upper limit (UL) of the 
95% CI of the difference between the two treatments 
(UL=1.156) was below 1.5 mmHg, confirming the non-
inferiority of the PF-formulation to the BAK-preserved 
product.  
 
Med Hypothesis Discov Innov Ophthalmol. 2020; 9(4)  
260 NON-INFERIORITY EVALUATION OF PF XALACOM VERSUS XALACOM IN PATIENTS WITH HIGH IOP 
 
 
Figure 2. Change in mean IOP for the preservative-free and BAK-preserved treatment groups, as measured at 08:00 AM during the four study visits (day 
0 and weeks 2, 6, 12). Error bars represent the ± SD of the mean.  Abbreviations: IOP, intraocular pressure; mmHg, millimeters of mercury; SD, standard 
deviation; preservative-free eye drops, preservative-free test formulation (Latanoprost 50 μg/ml + Timolol 5mg/ml eye drops solution); BAK-preserved 






Table 2. Mean ± SD and 95% CIs of the IOP change from baseline to the pre-specified time points for the preservative-free (PF) and BAK-preserved (BAK) 
formulations for the per-protocol population.    
Time (h)                                                                               Mean ± SD IOP (mmHg) 
Primary efficacy endpoint 
                       Baseline                                                                        Week 12 
PF BAK PF BAK Difference a 95% CI b P-value 
8:00 AM 24.60±2.07 25.03±2.39 16.72±2.89 16.37±2.90 0.624 -0.094, 1.341 0.088 
Secondary efficacy endpoints 
                        Baseline                                                                        Week 2 
PF BAK PF BAK Difference 95% CI P-value 
8:00 AM 24.60±2.07 25.03±2.39 17.83±2.79 17.92±2.85 0.121 -0.617, 0.858 0.747 
12:00 PM 24.36±1.71 24.79±2.19 17.43±2.74 17.71±2.83 0.049 -0.783, 0.684 0.894 
4:00 PM 24.37±1.85 24.44±2.00 17.51±2.90 17.50±2.80 0.044 -0.710, 0.798 0.908 
                        Baseline                                                                        Week 6 
PF BAK PF BAK Difference 95% CI P-value 
8:00 AM 24.60±2.07 25.03±2.39 16.95±2.69 16.71±2.97 0.511 -0.188, 1.210 0.151 
12:00 PM 24.36±1.71 24.79±2.19 16.57±2.47 16.35±2.77 0.471 -0.197, 1.139 0.166 
4:00 PM 24.37±1.85 24.44±2.00 16.46±2.61 16.35±2.86 0.152 -0.572, 0.875 0.680 
                        Baseline                                                                        Week 12 
PF BAK PF BAK Difference 95% CI P-value 
12:00 PM 24.36±1.71 24.79±2.19 16.31±2.64 16.01±2.57 0.569 -0.086, 1.225 0.088 
4:00 PM 24.37±1.85 24.44±2.00 16.22±2.65 15.94±2.52 0.306 -0.392, 1.003 0.388 
aPF minus BAK; bFor all primary and secondary endpoints, the results were not significant (P > 0.05). Abbreviations: Preservative-free formulation, 
Latanoprost 50 μg/ml + Timolol 5mg/ml eye drops solution; BAK-preserved formulation,  Benzalkonium chloride-preserved formulation (Xalacom™); SD, 
Standard deviation; IOP, intraocular pressure; millimeter of mercury, mmHg; CI, Confidence interval; %, percentage; h, hour; AM, means before midday; 
PM, means after midday. 
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Safety and Tolerability 
Overall, the incidence of adverse events was low in both 
treatment groups, and no serious adverse events were 
reported for the two formulations. In total, 78 patients in the 
clinical trial experienced AEs. Seventy-four of those patients ( 
35.3% of total patients) had ocular AEs: 34 patients were in the 
preservative-free group, and 40 were in the BAK-preserved 
group. Four patients in the PF group and one in the BAK group 
had systemic effects, whereas one subject presented skin and 
subcutaneous tissue AEs in the BAK group. The total number 
of reported AEs was 130: 123 were ocular, with 53 (43.1%) in 
the PF group and 70 (56.9%) in the BAK group (Table 3). 
Regarding the severity of the ocular AEs, 47 cases (88.7%) in 
the PF group and 57 (81.4%) in the BAK-group were considered 
mild, whereas 6 (11.3%) in the PF group and 13 (18.6%) in the 
BAK group were considered moderate. No clinically significant 
difference between the visual acuity changes caused by the 
treatments from baseline was observed.  
DISCUSSION 
In this randomized non-inferiority study, the developed 
preservative-free, multi-dose latanoprost 50 μg/mL + timolol 5 
mg/mL eye drops solution (Pharmathen S.A.) demonstrated 
non-inferior efficacy, compared with the marketed BAK-
preserved formulation over the 12-week treatment period. A 
similar reduction in IOP was recorded during the first 
assessment (i.e., week 2) for both products, which was 
maintained to the end of the study (week 12). The percentage 
reduction in IOP from baseline to the end of week 12 was -32% 
for the preservative-free solution group and -34% for the BAK-
preserved solution, corresponding to the upper limit for the 
95% CI for the difference between the two treatments, which 
was below the non-inferiority margin of 1.5 mmHg [16, 17].  
The need for the sterility of multi-dose eye drops has led to the 
inclusion of potent antimicrobial agents in these solutions. BAK 
is one of the most widely used preservatives for currently 
available ophthalmic solutions. It is a highly effective 
preservative agent with broad activity against gram-positive 
and gram-negative bacteria and fungi [6]. BAK is a quaternary 
ammonium that acts as a cationic detergent, exerting its 
antimicrobial activity by dissolving bacterial walls and 
membranes and damaging cytoplasmic contents. However, its 
ability to damage unicellular microbes does not seem to be 
confined to microbial cells; its effects may be exerted on 
human ocular cells as well, especially during long-term 
exposure [5, 18]. These effects are largely relevant for 
glaucoma patients who use several ophthalmic solutions 
multiple times per day for their lifetime [6]. 
 
Table 3. Summary of AEs for the Safety population associated with the preservative-free (PF) and BAK-preserved (BAK) formulations.  
 PF (Test, N = 96) BAK (Control, N = 100) 
Deaths or Serious AEs - - 
Discontinuation due to AE(s) 1 - 
Total number of AEs 57 73 
OCULAR AEs 53 70 
 Mild Moderate Mild  Moderate 
Diplopia 1 - - - 
Eye/eyelid pruritus 6 - 2 - 
Eye/eyelid pain 4 - 9 1 
Eye dryness  2 1 2 - 
Lacrimation increased 1 - - - 
Burning sensation  1 - 3 2 
Blurred vision  4 - 3 1 
Application site irritation  2 - 1 - 
Foreign body sensation  5 2 11 1 
Eye irritation 2 - - - 
Visual impairment  1 - 1 - 
IOP increased  13 - 15 - 
Vitreous floaters 1 - - - 
Conjuctival hyperaemia  4 3 6 7 
Abnormal sensation in the eye - - 2 - 
Instillation site burning - - 1 1 
Ocular hyperemia (upon waking up) - - 1 - 
SYSTEMIC AEs 4 3 
 Mild Moderate Severe Mild Moderate Severe 
Dizziness 1 - - - - - 
Headache 1 1 - - - - 
Oedema peripheral - - 1 - - - 
Dermatitis  - - - 1 - - 
Heart rate decreased - - - 1 - - 
Erythema of eyelid - - - 1 - - 
Abbreviations: AE, Adverse events; PF, preservative-free test formulation (Latanoprost 50 μg/ml + Timolol 5mg/ml eye drops solution); BAK,  BAK-
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In this context, several ophthalmic formulations have 
been developed as BAK-free or preservative-free recently 
[6]. Ophthalmic solutions using non-BAK preservatives, 
such as polyquad, sodium benzoate, and SofZia, have 
shown improved tolerance; however, some effects have 
also been observed with these antimicrobial agents. 
Therefore, efforts have been made to minimize the overall 
preservative exposure of patients, either by decreasing 
the number of administered drops or by decreasing or 
even eliminating the preservatives from these 
formulations [6]. In this regard, numerous preservative-
free formulations are currently available, including 
timolol, latanoprost, the fixed combination of timolol and 
latanoprost, betaxolol, dorzolamide, carteolol, and 
tafluprost [13]. These preservative-free ophthalmic 
solutions have demonstrated effectiveness in controlling 
IOP comparable to that of BAK-preserved formulations 
[6], suggesting that BAK, apart from its preservative 
activity, does not affect the ability of the drug to lower IOP 
[19]. To date, clinical studies that have compared the 
efficacy and tolerability of BAK-preserved and non-
preserved preparations of timolol [6, 10], latanoprost [20, 
21], carteolol [22], and tafluprost [23, 24] have 
demonstrated similar efficacy profiles. 
Preservative-free ophthalmic solutions, however, also 
have disadvantages. These formulations are marketed as 
sterile single-dose units, and the higher cost of these 
dosage forms and the handling limitations leading to their 
contamination have been recorded [6]. To address these 
issues, preservative-free multi-dose formulations, which 
are capable of preventing contamination while 
maintaining the high cost-effectiveness of the product, 
have also been developed [13, 15]. 
The currently evaluated latanoprost 50 μg/mL + timolol 5 
mg/mL eye drop by Pharmathen S.A. is a multi-dose 
preservative-free formulation with a three-stage 
contamination protection system; the system includes a 
specially designed adsorption filter, a silver spiral at the 
top of the tip used to prevent bacterial growth, and a 
special valve system (Aero Pump 3K technology) that 
blocks the solution backflow hindering bacterial 
penetration. The current phase III study demonstrated the 
non-inferiority of this ophthalmic solution product to the 
original BAK-preserved formulation (XalacomTM, Pfizer 
Ltd.) in reducing IOP over 12 weeks. The current study has 
several limitations. Initially, this was a single-blinded 
study, since the differences between the packaging 
systems of the two products made the double-masking 
unfeasible. This may have affected the perception of the 
received treatment by the patients. Nevertheless, the 
masking of the principal investigator was ensured through 
the study procedures and appropriate training of the rest 
of the study staff and participants. Other potential 
limitations include the designation of a single-morning IOP 
assessment as the primary non-inferiority endpoint and 
the relatively short study duration, which may have 
prevented the coverage of the potential long-term effects 
of the administered treatments. However, this endpoint 
and study design have been well-established for the 
demonstration of IOP-lowering activities of topical 
antiglaucoma agents.  
Preservative-free anti-glaucoma therapy is a realistic 
target for the future. The evidence demonstrating that a 
considerable proportion of topical adverse events may 
result from preservatives rather than active agents is 
growing. Therefore, an effort to reduce the overall 
preservative load for patients is essential. Nevertheless, 
preservative-free preparations remain expensive and, for 
some, inconvenient to use. In the future, it is anticipated 
that the development of new technologies and the 
introduction of novel multidose preservative-free 
systems, such as what was used for the 
latanoprost/timolol eye drop evaluated in this study, will 
allow more patients to administer preservative-free 
antiglaucoma medications.  
 
CONCLUSIONS 
Overall, the present study confirmed the non-inferiority of 
the developed PF-latanoprost/timolol eye formulations to 
the BAK-preserved control formulation in lowering IOP 
and based on its safety profile. The new PF-
latanoprost/timolol combination may offer an adequate 
IOP-lowering effect that is comparable to that obtained 
with existing preserved formulations. It may prove 
beneficial in cases where long-term topical treatment is 
required and in patients with ocular comorbidities.  
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